Posted by Michael Wonder on 30 Jan 2024
Takeda’s Hyqvia approved by European Commission as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy
30 January 2024 - At home or in office administration provides CIDP patients with a personalised treatment experience.
Takeda today announced that the European Commission approved Hyqvia [immune globulin infusion 10% (human) with recombinant human hyaluronidase] as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy after stabilisation with intravenous immunoglobulin therapy.
